- $105.94bn
- $124.85bn
- $32.36bn
- 86
- 51
- 88
- 89
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 14.19 | ||
PEG Ratio (f) | 2.08 | ||
EPS Growth (f) | 7.33% | ||
Dividend Yield (f) | 3.54% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.15 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 19.38 | ||
Price to Sales | 3.19 | ||
EV to EBITDA | 15.14 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 7.13% | ||
Return on Equity | 8.45% | ||
Operating Margin | 16.78% |
Financial Summary
Year End 26th Apr | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 28,913 | 30,117 | 31,686 | 31,227 | 32,364 | 33,489.86 | 34,974.84 | 1.16% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -4.18 | -13.87 | +28.97 | -36.04 | +34.46 | +38.16 | +6.9 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
Directors
- Geoffrey Martha CHM (51)
- Karen Parkhill CFO (55)
- Carol Surface CHO (55)
- Robert ten Hoedt EVP (60)
- John Liddicoat EVP (57)
- Sean Salmon EVP (56)
- Brett Wall EVP (56)
- Robert White EVP
- Richard Kuntz SVP (64)
- Jennifer Kirk CAO (46)
- Scott Donnelly LED (59)
- Richard Anderson IND (66)
- Craig Arnold IND (61)
- Andrea Goldsmith IND (57)
- Randall Hogan IND (65)
- Kevin Lofton IND (66)
- Elizabeth Nabel IND (69)
- Denise O'Leary IND (63)
- Kendall Powell IND (67)
- Last Annual
- April 26th, 2024
- Last Interim
- January 24th, 2025
- Incorporated
- June 12th, 2014
- Public Since
- November 21st, 1977
- No. of Shareholders
- 20,132
- No. of Employees
- 95,000
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
New York Stock Exchange
- Shares in Issue
- 1,282,543,505

- Address
- Building Two Parkmore Business Park West, DUBLIN, H91 4K49
- Web
- https://www.medtronic.com/
- Phone
- +353 14381700
- Contact
- Ryan Weispfenning
- Auditors
- PricewaterhouseCoopers LLP
Latest News for MDT
Upcoming Events for MDT
Q4 2025 Medtronic PLC Earnings Release
Q4 2025 Medtronic PLC Earnings Call
Q1 2026 Medtronic PLC Earnings Release
Q1 2026 Medtronic PLC Earnings Call
Medtronic PLC Annual Shareholders Meeting
Similar to MDT
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
Avanos Medical
New York Stock Exchange
FAQ
As of Today at 21:58 UTC, shares in Medtronic are trading at $82.60. This share price information is delayed by 15 minutes.
Shares in Medtronic last closed at $82.60 and the price had moved by +4.45% over the past 365 days. In terms of relative price strength the Medtronic share price has underperformed the S&P500 Index by -1.79% over the past year.
The overall consensus recommendation for Medtronic is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Medtronic dividend yield is 3.38% based on the trailing twelve month period.
Last year, Medtronic paid a total dividend of $2.79, and it currently has a trailing dividend yield of 3.38%. We do not have any data on when Medtronic is to next pay dividends.
We do not have data on when Medtronic is to next pay dividends. The historic dividend yield on Medtronic shares is currently 3.38%.
To buy shares in Medtronic you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $82.60, shares in Medtronic had a market capitalisation of $105.94bn.
Here are the trading details for Medtronic:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: MDT
Based on an overall assessment of its quality, value and momentum Medtronic is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Medtronic is $95.91. That is 16.11% above the last closing price of $82.60.
Analysts covering Medtronic currently have a consensus Earnings Per Share (EPS) forecast of $5.45 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medtronic. Over the past six months, its share price has underperformed the S&P500 Index by -0.77%.
As of the last closing price of $82.60, shares in Medtronic were trading -4.57% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Medtronic PE ratio based on its reported earnings over the past 12 months is 14.19. The shares last closed at $82.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Medtronic's management team is headed by:
- Geoffrey Martha - CHM
- Karen Parkhill - CFO
- Carol Surface - CHO
- Robert ten Hoedt - EVP
- John Liddicoat - EVP
- Sean Salmon - EVP
- Brett Wall - EVP
- Robert White - EVP
- Richard Kuntz - SVP
- Jennifer Kirk - CAO
- Scott Donnelly - LED
- Richard Anderson - IND
- Craig Arnold - IND
- Andrea Goldsmith - IND
- Randall Hogan - IND
- Kevin Lofton - IND
- Elizabeth Nabel - IND
- Denise O'Leary - IND
- Kendall Powell - IND